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Abstract
Objective: Available reports on adherence to recommended guidelines for labeling of probiotic products are
based on assessment of these products in developed countries. In the Arabian Gulf region, there is a paucity
of data on the characterization of probiotic products and an absence of local guidelines for their labeling. This
study, carried out in the United Arab Emirates (UAE), represents the first evaluation of probiotic products
available in the Arabian Peninsula.
Methods: Probiotic products were purchased over the counter from avarietyof sources, including pharmacies,
healthfood stores, and supermarkets across the UAE. All identified products were listed and information
regarding type of product preparation and labeling information were recorded.
Results: A total of 37 probiotic products, 15 dairy-based and 22 non-dairy-based were identified. The dairy
products comprised of 12 yogurts, two fermented milk products and one powdered baby formula. The
majority of non-dairy products were in capsule form (n16). While all the non-dairy products gave
information about the strain of probiotic microorganism and number present at time of manufacture, this
information was provided for only one dairy-based product. Strains of Lactobacillus acidophilus were the
most common probiotic organisms identified. However, one probiotic product listed Enterococcus faecalis
(750 million viable bacteria per capsule) as a component. With the exception of one non-dairy-based product,
all health-related claims were structure/function statements, according to the US Food and Drug
Administration nomenclature.
Conclusion: These findings indicate that awide variety of probiotic products are available in the Arabian Gulf.
Development of guidelines for labeling of these probiotic products and use of structure/function statements
and health claims should be addressed.
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P
robiotics are defined as live microorganisms that,
when administered in adequate amounts, confer
beneficial health effects (1, 2). In recent years, there
has been an upsurge in research into probiotics, as well as
growing commercial interest in the probiotic food/food
supplement concept. Dairy products, including yogurt,
fermented milk products and cheese, remain at the
forefront of probiotic food development. Probiotics now
constitute a sizeable portion of the functional food
market, which continues to show exponential market
growth estimated at a staggering $120 million per month
(3). Yogurts with added live probiotic strains are now
available in the marketplace and a number of these
products, which have emerged as leaders in the European
market, are also marketed internationally.
The commercial exploitation of the probiotic concept
is often associated with unsubstantiated claims of bene-
ficial effects. As probiotic products are not considered as
drugs, but rather as food supplements, they hitherto have
not been subjected to the same rigorous regulations
regarding efficacy, quality control, labeling, and consu-
mer information as normally applied to pharmaceutical
preparations. In 2002, a Working Group of the FAO/
WHO recommended that the following information be
described on the label of probiotic products: genus,
species and strain designation, minimum viable numbers
of each probiotic strain at the end of the shelf life,
suggested serving size to deliver the effective dose of
probiotics related to the health claim, health claim(s),
proper storage conditions and corporate contact details
for consumer information (1). Reports in literature
demonstrate that there are differences in the labeling
information provided for probiotic products available in
different countries with varying degrees of inaccuracies in
the information, all of which reflect the lack of interna-
tional consensus (411). However, these reports are based
on assessment of probiotic products in developed coun-
tries, and so far, there remains a paucity of data on the
products available in developing countries and the degree
of adherence to the FAO/WHO labeling guidelines in
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DOI: 10.3402/fnr.v53i0.1842these emerging markets (12). This study, carried out in
the United Arab Emirates (UAE), represents the first
evaluation of probiotic products available in the Arabian
Peninsula.
Methods
Probiotic products were purchased over the counter from
a variety of sources, including pharmacies, health food
stores, hypermarkets, and supermarkets. All the major
hypermarkets, supermarkets, and pharmacy chains with
multiple outlets around the country were included, and
randomly selected branches were visited over a 10-week
period from January to March 2008. To avoid selection
bias, all probiotic products on sale at any given location
were purchased. All identified products were listed and
information regarding type of product (tablet/capsule,
syrup, powdered form, dairy-based products, such as
yogurt and fermented milk), type of probiotic strains,
number of viable organisms and if this number was
guaranteed at time of manufacture and expiry date of
product, accuracy of organism identification and spelling
were recorded. The health-related claims on each product
were recorded.
Results
Thirty-seven probiotic products were identified, 15 dairy-
based and 22 non-dairy-based products. The dairy
products consisted of 12 yogurt products, two fermented
milk products and one powdered baby formula; all were
purchased from supermarkets/hypermarkets. Four of the
dairy products (Table 1; Nos. 9, 1214) were manufac-
tured in the region (Saudi Arabia and UAE). The other
products were imported from Europe and North Amer-
ica. Five products used ‘trademarked’ bacterial names to
identify the probiotic microorganisms present. An inter-
net search of the ‘trademarked’ names showed that these
represented specific probiotic bacteria strains. Only one
dairy product gave information about the strain of
probiotic microorganism using the proper scientific
name (L. casei shirota), and provided information about
the number of microorganisms present at time of
manufacture (Table 1). Six products did not list any
health-benefit claims. Among the products with health-
related claims, the most common was improvement of
digestive well being and regulation of digestion, using
statements like ‘promotes general digestive well being’
and ‘regulates the digestive process’. One product men-
tioned ‘maintenance of favorable balance of bacteria in
digestive system and fights harmful bacteria’, and
‘improved immunity’ was listed for two products.
The 22 non-dairy products were obtained from phar-
macies and health food stores. The majority of these were
capsules (16); others included two preparations in powder
form and one each as effervescent tablets, chewable
tablets and drinking straws. None of the products had
information leaflets as inserts in the package. Ten
products (45%) provided information on strain identifi-
cation of all or some of the probiotic microorganisms
they contained. A majority of these non-dairy probiotics
(59%) contained a blend of three to five probiotic
microorganisms (Table 2). Lactobacillus bulgaricus and
Streptococcus thermophilus, which are culture starters,
were listed as probiotic organisms in two products.
Enterococcus faecalis (750 million viable bacteria per
capsule) was listed as being present in one product. In
contrast to the dairy products, all the non-dairy products
gave information about the number of bacteria present at
the time of manufacture, but none stated how many will
be viable at the end of the products shelf life. Nine
products did not have any specific health-related claim
except for stating that these were food supplements. The
beneficial claims listed on the remaining products are
shown in Table 2.
Discussion
After many years of popularity in the Japanese and
European markets, probiotic products are now appearing
in new markets, including the Arabian Gulf region. The
number and diversity of probiotic products available
locally is high compared to other regions (13, 14). This
aptly reflects the increasing level of health awareness and
affluence, as well as the cosmopolitan nature of the
population. The provision of strain designation of the
probiotic organism and minimum viable numbers at the
end of the shelf life are important in determining the true
efficacy of the health-related claims of these products.
None of the studied products fulfilled all these criteria for
labeling, set up in the FAO/WHO recommendation (1).
The majority of probiotic products available in this
setting contain Lactobacillus and Bifidobacterium, which
are the main genera of Gram-positive bacteria currently
characterized as probiotics (15, 16). However, L. bulgar-
icus and S. thermophilus were found listed as probiotic
microorganisms in a number of preparations. It is
debatable whether or not these yogurt starter cultures
should be considered probiotics (17, 18). Although they
have been associated with improved lactose digestion and
immune enhancement, they fail to fulfill the criteria for a
probiotic microorganism, as they are sensitive to condi-
tions in the digestive tract and do not achieve very high
numbers in the gut (19). Safety concerns remain about
the other genera, such as Escherichia, Enterococcus, and
Saccharomyces, which have been marketed as probiotics
(2, 20, 21). It is of concern that one of the non-dairy
products contained Enterococcus, which is an important
cause of drug-resistant nosocomial infections. Recent
work has now demonstrated the transfer of virulence
determinants, from medical to food starter strains, in
Enterococcus via a natural conjugation process (21).
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bacterial strains present was a problem particularly
associated with dairy-based products, where only one
product provided the strain identification and number of
organisms present, as the beneficial effect attributed to
one strain cannot be assumed to be true of another strain
even when they are of the same species (22, 23). This lack
of information makes it difficult for the consumer to
objectively evaluate the attributed health-related claims.
For L. acidophilus, which was the most commonly named
probiotic organism, strain identification was only pro-
vided in nine products. The beneficial effects of L.
acidophilus remain inconclusive, but emerging data on
specific strains are indicative of a beneficial effect, thus
highlighting the importance of strain identification to
verify health-related claims (2, 23).
Among the products that stated the number of viable
organisms, none provided the numbers that would be
present at the end of the shelf life, although manufactur-
ing methods and maintenance of proper storage condi-
tions may affect the viability of organisms. In particular,
the stability of probiotics in powdered milk (including
infant formula) has been questioned, as the production
process is known to cause cell damage and loss of
viability of the probiotic cultures (24). Thus, from a
public health perspective, the number of organisms
expected to be viable under normal conditions at the
end of the shelf life is of relevance to ensure that the
consumer is ingesting an adequate dose of the probiotic.
Further work on microbial enumeration of the products
available in our setting is recommended.
The two most common health-related claims used were
that they maintain healthy intestinal flora and help to
improve digestion. Regulations relating to health claims
vary in different jurisdictions. In Japan, foods with health
claims are categorized into ‘Food with Nutrient Function
Claims’ and ‘Food for Specified Health Uses’ (FOSHU).
The latter contain dietary ingredients that have beneficial
effects on the physiological functions of the human body,
maintain and promote health, and improve health-related
conditions. But claims of disease-risk reduction are, with
the exception of calcium and folic acid (25), currently not
allowed under FOSHU. In 2007, the European Union
introduced a regulation on nutrition and health claims
made on foods, which should provide the opportunity for
the use of health claims, and in this case include claims of
disease-risk reduction (26). In the United States, a health-
related claim is statutorily defined as a statement that
expressly or by implication relates any substance in food
or dietary supplement to a disease or health-related
condition (27, 28). In contrast, structure/function claims
are statements regarding the effect of a food or dietary
supplement on the structure or function of the body; they
cannot address diseases, but may be directed at healthy
states (27, 28). The level of substantiation needed for
structure/function claims is regarded by some regulations
Table 1. Characteristics of dairy-based products
Product no. Product type Types of probiotic
species present
Organisms and No.
a (per suggested serving) Claim of beneficial effect
1 Yogurt 3 L. acidophilus; Bifidus longum; Streptococcus
thermophilus
None
2 Yogurt Not stated Not stated None
3 Yogurt Not stated Not stated None
4 Yogurt 2 L. acidophilus; L. bifidus None
5 Yogurt Not stated L. acidophilus; L. bifidus Promotes general digestive well being
6 Yogurt Not stated Not stated Healthy digestive system
7 Fermented milk 1 L. casei shirota 10
10 or 6.5 billion per bottle
a Healthy gut immunity
8 Yogurt Not stated NS None
9 Yogurt 1 Bifidus essensis† (trademarked) Regulates the digestive process
10 Yogurt Not stated Bifidus regularis† (trademarked) Regulates intestinal transit time
11 Milk drink Not stated Lactobacillus casei defensis† (trademarked) None
12 Laban
b Not stated Bifidus essensis† (trademarked) Improves digestion naturally
13 Laban
b 1 Gefilac† (trademarked) Maintains favorable balance of bacteria
in digestive system; fights harmful
bacteria
14 Laban
b 2 L. acidophilus LA5; B. bifidus BB12 Improves digestion, boosts immunity
15 Baby formula 1 Not stated None
aNumber present at time of manufacture.
bTraditional yogurt drink in the Middle East.
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(page number not for citation purpose)Table 2. Characteristics of non-dairy-based products
Product
no.
Product
type
Types of probiotic
species present
Organisms and No.
a (per suggested serving) Claim of beneficial effect
1 Powder 4 L. acidophilus CUL-21 (6 billion); L. crispatus (500
million); L. rhamnosus (7.5 billion); B. bifidum (1 billion);
L. lactis CU-34 (1 billion)
None
2 Capsule 4 L. acidophilus CUL-21 (6 billion); L. crispatus (500
million); L. rhamnosus (7.5 billion); B. bifidum (1 billion);
L. lactis CU-34 (1 billion)
None
3 Capsule 1 L. acidophilus (2 billion) None
4 Capsule 1 L. acidophilus (630 million) None
5 Capsule 1 B. infantis (4 billion) None
6 Capsule 2 L. acidophilusB. bifidum (1 billion) None
7 Drinking straw 1 L. acidophilus LA-14 (500 million) None
8 Powder 3 L. acidophilus CLT and CUL-21 (33.3 billion); L.
bulgaricus CUL-66 (33.3 billion); B. bifidum CUL-17 and
CUL-21 (33.3 billion)
None
9 Capsule 2 L. acidophilus LA5 (250 million); B. lactis BB12
(250 million)
Healthy intestinal flora
10 Capsule 4 B. lactis BB12 (1.25 billion); L. acidophilus LA (1.25
billion); L. paracasei 431 (1.25 billion); L. rhamnosus
GG (1.25 billion)
Healthy intestinal flora
11 Capsule 5 L. acidophilus LA5 (300 million); L. rhamnosus GG
(300 million); L. casei and L. casei 431 (300 million);
S. thermophilus (300 million)
Maintain healthy intestinal flora
12 Powder 3 B. bifidum (350 million); S. thermophilus (350 million);
B. infantis (350 million)
GI support
13 Capsule 1 L. acidophilus LA5 (500 million) Healthy intestinal flora
14 Capsule 4 Enterococcus faecalis (750 million); L. acidophilus
(2 billion); B. longum (250 million); B. bifidum
(250 million)
Healthy digestion, overall well being
15 Chewable
tablets
4 Blend of B. infantisB. adolescentisB. longum
B. bifidumB. coagularis (1 billion)
Lactic flora accelerant
16 Capsule 5 Blend of L. acidophilusL. brevisL. salivarius
L. bulgaricusL. bifidus (3 billion)
Supports favorable environment for
nutrients; encourages intestinal flora
balancepromotes healthy functioning
of intestinal system
17 Capsule 3 L. acidophilus (500 million); B. lactis (500 million);
S. thermophilus (500 million)
Maintain healthy digestion; support
microflora in case of inbalance during or
after antibiotics; mild cases of diarrhea
18 Effervescent
tablets
1 Lactic acid bacilli (4010
6) Maintain healthy intestine
19 Capsule 2 L. acidophilus LA5B. infantis (4 billion) Maintain healthy intestinal flora
20 Capsule 4 L. acidophilusB. longumB. caseiB. infantis
(500 million)
None
21 Capsule 3 L. acidophilusL. lactisB. bifidum (1 billion) Maintain healthy intestinal flora
22 Capsule 3 L. acidophilus CUL-21 (6 billion); L. crispatus
(500 million); L. rhamnosus (7.5 billion); B. bifidum
(1 billion); L. lactis CU-34 (1 billion)
Healthy intestinal flora
aNumber present at time of manufacture.
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(page number not for citation purpose)as being significantly lower than that for health claims
with respect to the type of studies, limitations of the data
and conclusiveness of the findings.
The health-benefit claims made for all but one of these
products could be classified as structure-function state-
ments, according to the nomenclature used in the United
States. One non-dairy capsule formulation had the
statement ‘support microflora in case of imbalance
during or after antibiotics; useful in mild cases of
diarrhea.’ This may be regarded as a medicinal claim
rather than a health claim, and although B. lactis was
listed as being present in this preparation, there was no
information on the strain. This makes verification of this
claim rather difficult, as this beneficial effect has been
demonstrated conclusively for B. lactis BB-12 only (29).
In view of the public health implications, there is an
urgent need for international regulations to address this
worrying trend of using structure/function claims, which
places a less stringent onus on manufacturers for the
scientific substantiation of these claims. The European
Commission supported ‘Process for the Assessment of
Scientific Support for Claims on Foods’, established a
defined set of criteria for the scientific substantiation of
health claims, a much-needed positive approach (26).
These criteria represent a scientifically robust tool, which
should be useful in assisting manufacturers in preparing
applications for health claims, and provide a reference for
regulatory bodies responsible for evaluating the scientific
evidence for these claims. In Europe, structure/function
claims would fall under the definition of health claims
and require the same high level of scientific substantia-
tion, as is the case with the newly introduced EU
regulation (26). This report provides the first insight
into the availability of probiotic products in the Arabian
Pennisula and the findings indicate that a wide variety of
products are available. However, the deficiencies in
meeting FAO/WHO recommended guidelines and devel-
opment of local/regional guidelines based on other
international models should be addressed. Further work
to enumerate the microbial content of these products is
recommended.
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